ReviewAmerican journal of hematology2026
2026 Update on the Management of Diffuse Large B-Cell Lymphoma.
Review in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Article
- Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat.Journal of clinical medicine · 2026Review
- Soluble E-Cadherin as a New Prognostic Biomarker Able to Predict Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma.Biomolecules · 2026Article
- Primary splenic diffuse large B-cell lymphoma masquerading as systemic lupus erythematosus: a case report.Frontiers in medicine · 2026Article
- Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R-CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola-R-CHP and R-CHOP, whereas elderly or frail/unfit patients may be treated with R-mini-CHOP or palliation. Frontline trials aim to improve outcomes for patients with high-risk disease utilizing R-CHOP + novel agents, CAR-T, and bispecific antibodies. Trials in the elderly/unfit population are minimizing and omitting chemotherapy. Risk-adapted approaches targeting cell of origin (COO) and utilizing interim PET imaging or ctDNA to guide therapy escalation or deescalation remain under investigation. Second line therapy curative-intent approaches include CAR-T or autologous stem cell transplantation, depending upon timing of disease progression after first-line therapy. In the relapsed/refractory setting, there has been a rapid growth in the therapeutic armamentarium, including bispecific antibody combinations with chemotherapy, bispecific antibodies with antibody-drug conjugates, and brentuximab vedotin + lenalidomide + rituximab. Multiple novel trials are further advancing the field away from chemotherapy including targeted therapy-antibody combinations, new bispecific antibodies and bispecific antibody combinations, immunomodulatory agents, and cellular therapy. In this review, we summarize recent data and discuss ongoing efforts to improve the management of DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.